AIM: To identify which drugs are associated with reports of suspected hepatic injury in children and adolescents. METHODS: Using a worldwide pharmacovigilance database, VigiBase, we conducted a case/non-case study on suspected adverse drug reactions (ADRs) occurring in the population <18 years old. Cases were all the records with hepatic ADRs and non-cases were all the other ADR records. Records regarding topically administered drugs were excluded from both groups. The association between drug and suspected hepatic ADRs was calculated using the reporting odds ratio (ROR) as a measure of disproportionality while adjusting for gender, country, reporter and calendar year. Sub-analyses were performed within therapeutic class and by excluding vaccination-related reports to reduce confounding. RESULTS: Overall, 6595 (1%) out of 624 673 ADR records in children and adolescents concerned hepatic injury. Most of the reported hepatic injuries concerned children 12-17 years of age. Drugs that were most frequently reported as suspected cause and were associated with hepatic injury comprised paracetamol, valproic acid, carbamazepine, methotrexate, minocycline, zidovudine, pemoline, ceftriaxone, bosentan, ciclosporin, atomoxetine, olanzapine, basiliximab, erythromycin and voriconazole. The association between hepatotoxicity and all these drugs, except for basiliximab, is already known. CONCLUSIONS: Drug-induced hepatic injury is infrequently reported (only 1% of total) as a suspected ADR in children and adolescents. The drugs associated with reported hepatotoxicity (paracetamol, antiepileptic and anti-tuberculosis agents) are known to be hepatotoxic in adults as well, but age related changes in associations were observed. VigiBase is useful as a start to plan further drug safety studies in children.
AIM: To identify which drugs are associated with reports of suspected hepatic injury in children and adolescents. METHODS: Using a worldwide pharmacovigilance database, VigiBase, we conducted a case/non-case study on suspected adverse drug reactions (ADRs) occurring in the population <18 years old. Cases were all the records with hepatic ADRs and non-cases were all the other ADR records. Records regarding topically administered drugs were excluded from both groups. The association between drug and suspected hepatic ADRs was calculated using the reporting odds ratio (ROR) as a measure of disproportionality while adjusting for gender, country, reporter and calendar year. Sub-analyses were performed within therapeutic class and by excluding vaccination-related reports to reduce confounding. RESULTS: Overall, 6595 (1%) out of 624 673 ADR records in children and adolescents concerned hepatic injury. Most of the reported hepatic injuries concerned children 12-17 years of age. Drugs that were most frequently reported as suspected cause and were associated with hepatic injury comprised paracetamol, valproic acid, carbamazepine, methotrexate, minocycline, zidovudine, pemoline, ceftriaxone, bosentan, ciclosporin, atomoxetine, olanzapine, basiliximab, erythromycin and voriconazole. The association between hepatotoxicity and all these drugs, except for basiliximab, is already known. CONCLUSIONS: Drug-induced hepatic injury is infrequently reported (only 1% of total) as a suspected ADR in children and adolescents. The drugs associated with reported hepatotoxicity (paracetamol, antiepileptic and anti-tuberculosis agents) are known to be hepatotoxic in adults as well, but age related changes in associations were observed. VigiBase is useful as a start to plan further drug safety studies in children.
Authors: Eugène P van Puijenbroek; Andrew Bate; Hubert G M Leufkens; Marie Lindquist; Roland Orre; Antoine C G Egberts Journal: Pharmacoepidemiol Drug Saf Date: 2002 Jan-Feb Impact factor: 2.890
Authors: Peter G M van der Heijden; Eugène P van Puijenbroek; Stef van Buuren; Jacques W van der Hofstede Journal: Stat Med Date: 2002-07-30 Impact factor: 2.373
Authors: Robert H Squires; Benjamin L Shneider; John Bucuvalas; Estella Alonso; Ronald J Sokol; Michael R Narkewicz; Anil Dhawan; Philip Rosenthal; Norberto Rodriguez-Baez; Karen F Murray; Simon Horslen; Martin G Martin; M James Lopez; Humberto Soriano; Brendan M McGuire; Maureen M Jonas; Nada Yazigi; Ross W Shepherd; Kathleen Schwarz; Steven Lobritto; Daniel W Thomas; Joel E Lavine; Saul Karpen; Vicky Ng; Deirdre Kelly; Nancy Simonds; Linda S Hynan Journal: J Pediatr Date: 2006-05 Impact factor: 4.406
Authors: William A Bower; Matthew Johns; Harold S Margolis; Ian T Williams; Beth P Bell Journal: Am J Gastroenterol Date: 2007-06-29 Impact factor: 10.864
Authors: Miriam C J M Sturkenboom; Katia M C Verhamme; Alfredo Nicolosi; Macey L Murray; Antje Neubert; Daan Caudri; Gino Picelli; Elif Fatma Sen; Carlo Giaquinto; Luigi Cantarutti; Paola Baiardi; Maria-Grazia Felisi; Adriana Ceci; Ian C K Wong Journal: BMJ Date: 2008-11-24
Authors: Carmen Ferrajolo; Preciosa M Coloma; Katia M C Verhamme; Martijn J Schuemie; Sandra de Bie; Rosa Gini; Ron Herings; Giampiero Mazzaglia; Gino Picelli; Carlo Giaquinto; Lorenza Scotti; Paul Avillach; Lars Pedersen; Francesco Rossi; Annalisa Capuano; Johan van der Lei; Gianluca Trifiró; Miriam C J M Sturkenboom Journal: Drug Saf Date: 2014-02 Impact factor: 5.606
Authors: Carmen Ferrajolo; Katia M C Verhamme; Gianluca Trifirò; Geert W 't Jong; Carlo Giaquinto; Gino Picelli; Alessandro Oteri; Sandra de Bie; Vera E Valkhoff; Martijn J Schuemie; Giampiero Mazzaglia; Claudio Cricelli; Francesco Rossi; Annalisa Capuano; Miriam C J M Sturkenboom Journal: Drug Saf Date: 2013-10 Impact factor: 5.606